Trials / Completed
CompletedNCT01716598
Evaluation of the IPS System for TLD Therapy in Patients With COPD
IPS-II Study: Evaluation of the Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation (TLD) Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD) - A Pilot Study.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Nuvaira, Inc. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Targeted Lung Denervation (TLD) Therapy will be a safe method to ablate the airway nerve trunks that travel parallel to and outside of the main bronchi and into the lungs to achieve targeted lung denervation and potentially improve breathing and quality of life for patients suffering from COPD. Use of the IPS System will be technically feasible in accessing the target treatment location and delivering RF energy to the target treatment location.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | IPS System | TLD Therapy will be achieved bronchoscopically. |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2014-05-01
- Completion
- 2016-04-01
- First posted
- 2012-10-30
- Last updated
- 2016-09-23
Locations
4 sites across 2 countries: Austria, France
Source: ClinicalTrials.gov record NCT01716598. Inclusion in this directory is not an endorsement.